Mundipharma has called in Red Health to handle the European launch of its new rheumatoid arthritis treatment.

The treatment targets morning stiffness and pain associated with rheumatoid arthritis. The oral medication has been approved in the EU and Red has been brought in to help launch the treatment in European territories. The campaign will accentuate the need for the new product.

Pat Pearson, Head of Ethical Healthcare, said: “We’re really excited about this launch. We can see an opportunity to make a real difference for people with rheumatoid arthritis through creative communications interpreting stiffness and pain.”